Who we are

The current IVG membership is:

AbbVie

AbbVie have been creating innovative products and services for patients for over 70 years and continue to push the boundaries of what is possible in eye care. They have a global reputation for innovation in ocular surface disease, glaucoma, retinal disease and presbyopia.

For further information on the company and its people, portfolio, and commitments, please visit www.abbvie.co.uk.

Bayer

Bayer is a life science company with a more than 150-year history. They focus on researching, developing, and marketing specialty-focused innovative medicines that provide significant clinical benefit and value. In ophthalmology, Bayer is helping reduce the number of people impacted globally by visual impairment through innovative products and research.

For further information on the company and its people, portfolio, and commitments, please visit www.bayer.co.uk/en/.

Novartis

Novartis develops, manufactures and markets innovative medicines, devices and diagnostic tests which help improve patient outcomes. They aim to develop life-changing pharmaceuticals and transformative technologies for diseases and conditions from the front to back of the eye and have pioneered many treatments, including for retinal diseases.

For further information on the company and its people, portfolio, and commitments, please visit www.novartis.co.uk.

Santen

Santen Pharmaceutical is one of the world’s leading specialist ophthalmic pharmaceutical companies, founded in Japan over a century ago and now serving patients all over the world. They’ve been active in the European market since 1994. They’re passionate about improving eye health and vision for patients and making beneficial treatments accessible to patients and healthcare systems. 

For further information on the company and its people, portfolio, and commitments, please visit www.santen.uk.

Roche

Roche Pharmaceuticals is focused on translating excellence in science into effective medicines for patients. In ophthalmology their clinical programmes focus on some of the main causes of blindness and visual impairment globally, where the unmet need is high.

For further information on the company and its people, portfolio, and commitments, please visit www.roche.co.uk.